Signal Peptidase Specificity and Substrate Selection: Influence of S1 and S3 Substrate Binding Pocket Residues on Spase I Cleavage Site Selection

Total Page:16

File Type:pdf, Size:1020Kb

Signal Peptidase Specificity and Substrate Selection: Influence of S1 and S3 Substrate Binding Pocket Residues on Spase I Cleavage Site Selection SIGNAL PEPTIDASE SPECIFICITY AND SUBSTRATE SELECTION: INFLUENCE OF S1 AND S3 SUBSTRATE BINDING POCKET RESIDUES ON SPASE I CLEAVAGE SITE SELECTION DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University Andrew Karla, B.S. ***** The Ohio State University 2005 Dissertation committee: Approved by Professor Ross E. Dalbey, Advisor Professor Ming-Daw Tsai Professor Sean Taylor Professor David J. Hart Advisor Chemistry Graduate Program ABSTRACT Signal peptidase, which removes signal peptides from preproteins, has a substrate specificity for small uncharged residues at -1 (P1) and small or larger aliphatic residues at the -3 (P3) position. Structures of the catalytic domain with a 5S-penem inhibitor and a lipopeptide inhibitor reveal candidate residues that make up the S1 and S3 pockets that bind the P1 and P3 specificity residues of the preprotein substrate. We have used site- directed mutagenesis, mass spectrometric analysis, in vivo and in vitro activity assays as well as molecular modeling to examine the importance of the substrate pocket residues in their ability to promote cleavage of the pro-OmpA-nuclease A substrate with WT and mutant processing regions. Generally, we find that the S1 and S3 binding sites can tolerate changes that are expected to increase or decrease the size of the pocket without large effects on activity. One residue that contributes to the high fidelity of cleavage of signal peptidase is the Ile 144 residue. Changes of the Ile 144 residue to cysteine result in cleavage at multiple sites, as determined by mass spectrometry and Edman sequencing analysis. In addition, we find that signal peptidase is able to cleave after phenylalanine at the -1 residue in a double mutant where both Ile 86 and Ile 144 were changed to an alanine. Also, alteration of the Ile 144 and Ile 86 residues to the corresponding residues found in the homologous Imp1 protease changes the specificity to promote cleavage ii following a –1 Asn residue. This work shows that Ile 144 and Ile 86 contribute to the signal peptidase substrate specificity and that Ile 144 is important for the accuracy of the cleavage reaction. Additionally, studies with corresponding β-lactamase substrate mutants were used to further investigate the altered specificity revealed in the pro-OmpA-nuclease A studies. The use of β-lactamase as a substrate allows for a convenient antibiotic selection method to assay for processing in vivo. In a preliminary study, a two plasmid system was developed to assay combinations of SPase and β-lactamase substrate mutants. This study assayed for growth of the temperature sensitive SPase strain, IT41, that was expressing various combinations of SPase and β-lactamase substrate mutants. Growth under conditions of high ampicillin concentration would suggest efficient processing of β- lactamase. Growth was observed in some cases when the β-lactamase substrate carried a relatively conservative -1V substitution in place of the WT -1A residue. The two-plasmid system utilizing the β-lactamase substrate developed in these studies has potential to be implemented in an unbiased genetic selection technique to further define the substrate specificity determinants of signal peptidase. The β-lactamase substrate was also assayed in a pulse-chase study to investigate processing by select SPase mutants found to affect specificity in the pro-OmpA-nuclease A studies. These studies largely confirm the results observed with the pro-OmpA- nuclease A substrate. One added benefit of using β-lactamase as a substrate is that the iii signal peptide cleavage region possesses no alternate cleavage sites which greatly simplifies data analysis. iv This work dedicated to my parents and my family v ACKNOWLEDGMENTS I would like to thank my advisor, Dr. Ross Dalbey, for his advice and guidance throughout my graduate studies. His continuing enthusiasm and support are to a great degree responsible for my success in these investigations. I would like to thank the other professors that have been involved in these studies directly as collaborators and indirectly as sources of valuable advice. Their continuing involvement has meant much to me: collaborators Dr. Mark Lively, Dr. Mark Paetzel, Dr. Natalie Strynadka; and others Dr. Ming-Daw Tsai, Dr. Dehua Pei and Dr. Martin Caffrey. I would also like to thank my graduate committee for their assistance in the development of this dissertation: Dr. Ming-Daw Tsai, Dr. Sean Taylor and Dr. David Hart. Also, I would like to express gratitude to my friends and coworkers in Johnston Lab. It is the involvement of these people that has made this experience not only an enriching one but also an enjoyable one: Li Zhao, Minyong Chen, Joseph Carlos, Fenglei Jiang, Özlem Doğan Ekici, Liang Yi, Hyunjin Cho, Eunjung Shim, Nil Celebi, Yuxia Dong, Kun Xie, Jijun Yuan and members of the Pei and Tsai research groups. vi Lastly, I would like to thank my parents Paul and Susan, my brother Stephen, my sisters Elizabeth and Margaret, and my fiancée Mary Cerny. I am forever grateful for the love and support they have given me over the years. vii VITA 1975……………………….. Born in Cleveland, Ohio 1998……………………….. B. S. in Biochemistry, University of Dayton, Dayton, Ohio 1998-Present……………….. Department of Chemistry, The Ohio State University, Columbus, Ohio. Fellowship support provided by the Chemistry Biology Interface Training Program and through support as a Graduate Teaching and Research Associate. PUBLICATIONS Karla A, Lively MO, Paetzel M, Dalbey RE (2005). The identification of residues that control signal peptidase cleavage fidelity and substrate specificity. J Biol Chem 280(8): 6731-41. Paetzel M, Karla A, Strynadka NC, Dalbey RE (2002). Signal peptidases. Chem Rev 102(12): 4549-80. Review. Carlos JL, Paetzel M, Brubaker G, Karla A, Ashwell CM, Lively MO, Cao G, Bullinger P, Dalbey RE (2000). The role of the membrane-spanning domain of type I signal peptidases in substrate cleavage site selection. J Biol Chem 275(49): 38813-22 viii FIELDS OF STUDY Major field: Chemistry Specific field: Signal peptidase and membrane protein insertion ix TABLE OF CONTENTS Abstract ……………………………………………………………………………. ii Dedication………………………………………………………………………….. v Acknowledgements………………………………………………………………… vi Vita………………………….……………………………………………………… viii List of Tables……………………………………………..……………………...… xii List of Figures…………………………………………….…………………...…… xiii Chapters: 1. Introduction………………………………….………………………...………… 1 1.1 Signal hypothesis………………………………….……………………….. 1 1.2 SPase I family of proteases………………………………….……….…..… 2 1.3 SPase I substrates: structure of signal peptides………………………...….. 6 1.4 Mechanism of type I SPases………………………………….………….… 7 1.5 Protein engineering: understanding and manipulating enzyme stability and specificity. ………………………………….………………... 12 2. The identification of residues that control signal peptidase cleavage fidelity and substrate specificity………………………………….………..…… 27 2.1 Introduction………………………………….………………………..….… 27 2.2 Results……………………………………………………………………… 29 2.2.1 In vitro analysis of SPase binding site mutants with the wild-type preprotein substrate……………………………………...… 29 2.2.2 In vitro analysis of SPase cleavage of pre-protein substrate mutants…………………………………………………………..…… 30 2.2.3 Mass Spectrometric analysis of signal peptide cleavage……….……. 31 2.2.4 In vivo analysis of signal peptidase binding site mutants………….… 36 2.2.5 Molecular modeling of binding site mutants of signal peptidase in complex with signal peptides…………………………..………..… 37 2.3 Discussion……………………………………………………………..…… 38 2.4 Materials and Methods………………………………………………..…… 45 2.4.1 Bacterials Strains and Plasmids……………………………………… 45 2.4.2 DNA methods……………………………………………………...… 45 2.4.3 Purification of signal peptidase and pro-OmpA-nuclease A…….… 46 x 2.4.4 In vitro and in vivo assay of Signal Peptidase Cleavage……….……. 46 2.4.5 Study to assay ability of mutants to complement the growth defect of the temperature-sensitive SPase strain, IT41(DE3)……..…. 47 2.4.6 Automated Edman Degradation…………………………………...…. 47 2.4.7 Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) Mass spectrometry………………………………...… 48 2.4.8 Prediction of theoretical mass for cleavage products…………...…… 49 2.4.9 Molecular Modeling……………………………………………….… 49 3. Analysis of cleavage fidelity and substrate specificity of signal peptidase S1/S3 mutants with β-lactamase substrate in vivo………………………….…… 67 3.1 Introduction………………………………………………………………… 67 3.2 Results: In vivo growth assays…………………………………………...… 69 3.2.1 WT β-lactamase……………………………………………………… 69 3.2.2 -1V β-lactamase……………………………………………………… 72 3.2.3 -1F β-lactamase…………………………………………………….… 73 3.2.4 -1N β-lactamase ……………………………………..……………..... 73 3.3 Discussion……………………………………………………………….…. 74 3.3.1 Genetic applications………………………………………..………… 78 3.4 Results: Pulse-Chase Studies of in vivo processing……………………...… 79 3.4.1 Processing of WT β-lactamase………………………………….…… 79 3.4.2 Processing of –1V β-lactamase………………………………….…… 80 3.4.3 Processing of –1F β-lactamase……………………………….……… 81 3.4.4 Processing of –1N β-lactamase………………………………….…… 82 3.5 Discussion…………………………………………………………….……. 83 3.6 Materials and Methods………………………………………………...…… 87 3.6.1 Bacterial strains and plasmids……………………………………...… 87 3.6.2 Construction of plasmids…………………………………………..… 87 3.6.3 Purification of β-lactamase……………………………..……………. 88 3.6.4 Pulse-chase assay of β-lactamase processing………………...……… 89 3.6.5 Growth assay for β-lactamase processing………………………….… 90 3.6.6
Recommended publications
  • The Secretory Proprotein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation
    The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation Nabil G. Seidah*†, Suzanne Benjannet*, Louise Wickham*, Jadwiga Marcinkiewicz*, Ste´phanie Be´langer Jasmin‡, Stefano Stifani‡, Ajoy Basak§, Annik Prat*, and Michel Chre´ tien§ *Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, QC, H2W 1R7 Canada; ‡Montreal Neurological Institute, McGill University, Montreal, QC, H3A 2B4 Canada; and §Regional Protein Chemistry Center and Diseases of Aging Unit, Ottawa Health Research Institute, Ottawa Hospital, Civic Campus, 725 Parkdale Avenue, Ottawa, ON, K1Y 4E9 Canada Edited by Donald F. Steiner, University of Chicago, Chicago, IL, and approved December 5, 2002 (received for review September 10, 2002) Seven secretory mammalian kexin-like subtilases have been iden- LP251 (Eli Lilly, patent no. WO 02͞14358 A2) recently cloned tified that cleave a variety of precursor proteins at monobasic and by two pharmaceutical companies. NARC-1 was identified via dibasic residues. The recently characterized pyrolysin-like subtilase the cloning of cDNAs up-regulated after apoptosis induced by SKI-1 cleaves proproteins at nonbasic residues. In this work we serum deprivation in primary cerebellar neurons, whereas LP251 describe the properties of a proteinase K-like subtilase, neural was discovered via global cloning of secretory proteins. Aside apoptosis-regulated convertase 1 (NARC-1), representing the ninth from the fact that NARC-1 mRNA is expressed in liver ϾϾ member of the secretory subtilase family. Biosynthetic and micro- testis Ͼ kidney and that the gene localizes to human chromo- sequencing analyses of WT and mutant enzyme revealed that some 1p33-p34.3, no information is available on NARC-1 ac- human and mouse pro-NARC-1 are autocatalytically and intramo- tivity, cleavage specificity, cellular and tissue expression, and lecularly processed into NARC-1 at the (Y,I)VV(V,L)(L,M)2 motif, a biological function.
    [Show full text]
  • Chymotrypsin: a Serine Protease Reaction Mechanism Step
    CHEM464/Medh,J.D. Catalytic Strategies Chymotrypsin: A serine protease • Covalent catalysis: temporary covalent modification of reactive • Hydrolyzes peptide bonds on the carboxyl side of group on enzyme active site Tyr, Phe, Trp, Met, Leu • Acid-Base catalysis: A molecule other than water is proton • Since peptide bond is highly unreactive, a strong donor or acceptor (nucleophilic or electrophilic attack) nucleophile is required for its hydrolysis • Metal ion catalysis: Involvement of metal ion in catalysis. A metal ion is an electrophile and (i) may stabilize a negative • Catalytic strategy is covalent modification and charge on an intermediate; (ii) by attracting electrons from acid-base catalysis water, renders water more acidic (prone to loose a proton); (iii) • Contains catalytic triad of Ser, His and Asp. Ser is may bind to substrate and reduce activation energy a nucleophile and participates in covalent • Catalysis by approximation: In reactions requiring more than modification, His is a proton acceptor (base), Asp one substrate, the enzyme facilitates their interaction by serving stabilizes His (and active site) by electrostatic as an adapter that increases proximity of the substrates to each interactions other Reaction Mechanism Step-wise reaction • Hydrolysis by chymotrypsin is a 2-step process • Enzyme active site is stabilized by ionic interactions • Step 1: serine reacts with substrate to form covalent between Asp and His and H-bond between His and Ser. ES complex • In the presence of a substrate, His accepts a proton from • Step 2: release of products from ES complex and Ser, Ser makes a nucleophilic attack on the peptide’s regeneration of enzyme carbonyl C converting its geometry to tetrahedral.
    [Show full text]
  • Chymotrypsin-Like Peptidases in Insects
    Chymotrypsin-like peptidases in insects Dissertation zur Erlangung des akademischen Grades Doctor rerum naturalium (Dr. rer. nat.) Fachbereich Biologie/Chemie der Universität Osnabrück vorgelegt von Gunnar Bröhan Osnabrück, Mai 2010 TABLE OF CONTENTS I Table of contents 1. Introduction 1 1.1. Serine endopeptidases 1 1.2. The structure of S1A chymotrypsin-like peptidases 2 1.3. Catalytic mechanism of chymotrypsin-like peptidases 6 1.4. Insect chymotrypsin-like peptidases 9 1.4.1. Chymotrypsin-like peptidases in insect immunity 9 1.4.2. Role of chymotrypsin-like peptidases in digestion 14 1.4.3. Involvement of chymotrypsin-like peptidases in molt 16 1.5. Objective of the work 18 2. Material and Methods 20 2.1. Material 20 2.1.1. Culture Media 20 2.1.2. Insects 20 2.2. Molecular biological methods 20 2.2.1. Tissue preparations for total RNA isolation 20 2.2.2. Total RNA isolation 21 2.2.3. Reverse transcription 21 2.2.4. Quantification of nucleic acids 21 2.2.5. Chemical competent Escherichia coli 21 2.2.6. Ligation and transformation in E. coli 21 2.2.7. Preparation of plasmid DNA 22 2.2.8. Restriction enzyme digestion of DNA 22 2.2.9. DNA gel-electrophoresis and DNA isolation 22 2.2.10. Polymerase-chain-reaction based methods 23 2.2.10.1. RACE-PCR 23 2.2.10.2. Quantitative Realtime PCR 23 2.2.10.3. Megaprimer PCR 24 2.2.11. Cloning of insect CTLPs 25 2.2.12. Syntheses of Digoxigenin-labeled DNA and RNA probes 26 2.2.13.
    [Show full text]
  • J. Gen. Appl. Microbiol. Doi 10.2323/Jgam.2019.04.005 ©2019 Applied Microbiology, Molecular and Cellular Biosciences Research Foundation
    Advance Publication J. Gen. Appl. Microbiol. doi 10.2323/jgam.2019.04.005 ©2019 Applied Microbiology, Molecular and Cellular Biosciences Research Foundation 1 Genome Sequencing, Purification, and Biochemical Characterization of a 2 Strongly Fibrinolytic Enzyme from Bacillus amyloliquefaciens Jxnuwx-1 isolated 3 from Chinese Traditional Douchi 4 (Received November 29, 2018; Accepted April 22, 2019; J-STAGE Advance publication date: August 14, 2019) * 5 Huilin Yang, Lin Yang, Xiang Li, Hao Li, Zongcai Tu, Xiaolan Wang 6 Key Lab of Protection and Utilization of Subtropic Plant Resources of Jiangxi 7 Province, Jiangxi Normal University 99 Ziyang Road, Nanchang 330022, China * 8 Corresponding author: Xiaolan Wang, PhD, Key Lab of Protection and Utilization 9 of Subtropic Plant Resources of Jiangxi Province, Jiangxi Normal University 99 10 Ziyang Road, Nanchang 330022, China. Tel: 0086-791-88210391. 11 Email: [email protected]. 12 Short title: B. amyloliquefaciens fibrinolytic enzyme 13 14 * Key Lab of Protection and Utilization of Subtropic Plant Resources of Jiangxi Province, Jiangxi Normal University 99 Ziyang Road, Nanchang 330022, China. Email:[email protected] (X.Wang) 1 15 Abbreviation 16 CVDs: Cardiovascular diseases; u-PA: urokinase-type plasminogen activator; t-PA: 17 tissue plasminogen activator; PMSF: phenylmethanesulfonyl fluoride; SBTI: soybean 18 trypsin inhibitor; EDTA: ethylenediaminetetraacetic acid; TLCK: N-Tosyl-L-Lysine 19 chloromethyl ketone; TPCK: N-α-Tosyl-L-phenylalanine chloromethyl ketone; pNA: 20 p-nitroaniline; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel 21 electrophoresis; GO: Gene Ontology 2 22 23 Summary 24 A strongly fibrinolytic enzyme was purified from Bacillus amyloliquefaciens 25 Jxnuwx-1, found in Chinese traditional fermented black soya bean (douchi).
    [Show full text]
  • Structural and Biochemical Characterizations of Three Potential Drug Targets from Pathogens
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 2020 Structural and Biochemical Characterizations of Three Potential Drug Targets from Pathogens LU LU ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6214 ISBN 978-91-513-1148-7 UPPSALA urn:nbn:se:uu:diva-435815 2021 Dissertation presented at Uppsala University to be publicly examined in Room A1:111a, BMC, Husargatan 3, Uppsala, Friday, 16 April 2021 at 13:15 for the degree of Doctor of Philosophy. The examination will be conducted in English. Faculty examiner: Christian Cambillau. Abstract Lu, L. 2021. Structural and Biochemical Characterizations of Three Potential Drug Targets from Pathogens. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 2020. 91 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-1148-7. As antibiotic resistance of various pathogens emerged globally, the need for new effective drugs with novel modes of action became urgent. In this thesis, we focus on infectious diseases, e.g. tuberculosis, malaria, and nosocomial infections, and the corresponding causative pathogens, Mycobacterium tuberculosis, Plasmodium falciparum, and the Gram-negative ESKAPE pathogens that underlie so many healthcare-acquired diseases. Following the same- target-other-pathogen (STOP) strategy, we attempted to comprehensively explore the properties of three promising drug targets. Signal peptidase I (SPase I), existing both in Gram-negative and Gram-positive bacteria, as well as in parasites, is vital for cell viability, due to its critical role in signal peptide cleavage, thus, protein maturation, and secreted protein transport. Three factors, comprising essentiality, a unique mode of action, and easy accessibility, make it an attractive drug target.
    [Show full text]
  • Design of a Highly Selective Quenched Activity-Based Probe
    Article pubs.acs.org/JACS Design of a Highly Selective Quenched Activity-Based Probe and Its Application in Dual Color Imaging Studies of Cathepsin S Activity Localization † † † † ∥ Kristina Oresic Bender, Leslie Ofori, Wouter A. van der Linden, Elliot D. Mock, Gopal K. Datta, ∥ § † † ∥ # Somenath Chowdhury, Hao Li, Ehud Segal, Mateo Sanchez Lopez, Jonathan A. Ellman, , ⊥ † ‡ § † ⊥ Carl G. Figdor, Matthew Bogyo,*, , , and Martijn Verdoes*, , † ‡ § Departments of Pathology, Microbiology and Immunology, and Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, United States ∥ Department of Chemistry, University of California-Berkeley, Berkeley, California 94720, United States ⊥ Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6500 HB Nijmegen, The Netherlands *S Supporting Information ABSTRACT: The cysteine cathepsins are a group of 11 proteases whose function was originally believed to be the degradation of endocytosed material with a high degree of redundancy. However, it has become clear that these enzymes are also important regulators of both health and disease. Thus, selective tools that can discriminate between members of this highly related class of enzymes will be critical to further delineate the unique biological functions of individual cathepsins. Here we present the design and synthesis of a near-infrared quenched activity-based probe (qABP) that selectively targets cathepsin S which is highly expressed in immune cells. Importantly, this high degree of selectivity is retained both in vitro and in vivo. In combination with a new green-fluorescent pan-reactive cysteine cathepsin qABP we performed dual color labeling studies in bone marrow-derived immune cells and identified vesicles containing exclusively cathepsin S activity.
    [Show full text]
  • Towards Therapy for Batten Disease
    Towards therapy for Batten disease Mariana Catanho da Silva Vieira MRC Laboratory for Molecular Cell Biology University College London PhD Supervisor: Dr Sara E Mole A thesis submitted for the degree of Doctor of Philosophy University College London September 2014 Declaration I, Mariana Catanho da Silva Vieira, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Abstract The gene underlying the classic neurodegenerative lysosomal storage disorder (LSD) juvenile neuronal ceroid lipofuscinosis (JNCL) in humans, CLN3, encodes a polytopic membrane spanning protein of unknown function. Several studies using simpler models have been performed in order to further understand this protein and its pathological mechanism. Schizosaccharomyces pombe provides an ideal model organism for the study of CLN3 function, due to its simplicity, genetic tractability and the presence of a single orthologue of CLN3 (Btn1p), which exhibits a functional profile comparable to its human counterpart. In this study, this model was used to explore the effect of different mutations in btn1 as well as phenotypes arising from complete deletion of the gene. Different btn1 mutations have different effects on the protein function, underlining different phenotypes and affecting the levels of expression of Btn1p. So far, there is no cure for JNCL and therefore it is of great importance to identify novel lead compounds that can be developed for disease therapy. To identify these compounds, a drug screen with btn1Δ cells based on their sensitivity to cyclosporine A, was developed. Positive hits from the screen were validated and tested for their ability to rescue other specific phenotypes also associated with the loss of btn1.
    [Show full text]
  • House Dust Mites: Ecology, Biology, Prevalence, Epidemiology and Elimination Muhammad Sarwar
    Chapter House Dust Mites: Ecology, Biology, Prevalence, Epidemiology and Elimination Muhammad Sarwar Abstract House dust mites burrow cheerfully into our clothing, pillowcases, carpets, mats and furniture, and feed on human dead skin cells by breaking them into small particles for ingestion. Dust mites are most common in asthma allergens, and some people have a simple dust allergy, but others have an additional condition called atopic dermatitis, often stated to as eczema by reacting to mites with hideous itching and redness. The most common type of dust mites are Dermatophagoides farinae Hughes (American house dust mite) and Dermatophagoides pteronyssinus Trouessart (European house dust mite) of family Pyroglyphidae (Acari), which have been associated with dermatological and respiratory allergies in humans such as eczema and asthma. A typical house dust mite measures 0.2–0.3 mm and the body of mite has a striated cuticle. A mated female house dust mite can live up to 70 days and lays 60–100 eggs in the last 5 weeks of life, and an average life cycle is 65–100 days. In a 10-week life span, dust mite produces about 2000 fecal particles and an even larger number of partially digested enzyme-covered dust particles. They feed on skin flakes from animals, including humans and on some mold. Notably, mite’s gut contains potent digestive enzymes peptidase 1 that persist in their feces and are major induc- ers of allergic reactions, but its exoskeleton can also contribute this. Allergy testing by a physician can determine respiratory or dermatological symptoms to undergo allergen immunotherapy, by exposing to dust mite extracts for “training” immune system not to overreact.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Human Elastase 1: Evidence for Expression in the Skin and the Identi®Cation of a Frequent Frameshift Polymorphism
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Human Elastase 1: Evidence for Expression in the Skin and the Identi®cation of a Frequent Frameshift Polymorphism Ulvi Talas, John Dunlop,1 Sahera Khalaf , Irene M. Leigh, and David P. Kelsell Center for Cutaneous Research, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Whitechapel, London, U.K. Human pancreatic elastase 1 is a serine protease individuals with/without the keratoderma revealed a which maps to the chromosomal region 12q13 close sequence variant, which would result in a premature to a locus for an autosomal dominant skin disease, truncation of the protein. This sequence variant, diffuse nonepidermolytic palmoplantar keratoderma, however, did not segregate with the skin disease and, and was investigated as a possible candidate gene for indeed, was found to occur at a relatively high fre- this disorder. Expression of two elastase inhibitors, quency in the population. Individuals homozygous ela®n and SLPI, has been related to several hyper- for the variant do not have any obvious skin proliferative skin conditions. elastase 1 is functionally abnormalities. Based on the analysis of the secondary silent in the human pancreas but elastase 1 expres- structure of the translated putative protein, the sion at the mRNA level was detected in human truncation is unlikely to result in knock-out of the cultured primary keratinocytes. Antibody staining elastase, but may cause destabilization of the localized the protein to the basal cell layer of the enzyme±inhibitor complex. Key words: ela®n/keratino- human epidermis at a number of sites includingthe cyte/protein truncation/serine protease.
    [Show full text]
  • Secretion and Autoproteolytic Maturation of Subtilisin (Protein Transport/Proteolytic Processing/Mutagenesis) SCOTT D
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 3096-3100, May 1986 Biochemistry Secretion and autoproteolytic maturation of subtilisin (protein transport/proteolytic processing/mutagenesis) SCOTT D. POWER*, ROBIN M. ADAMS*, AND JAMES A. WELLSt *Department of Protein Chemistry, Genencor, Inc., 180 Kimball Way, South San Francisco, CA 94080; and tDepartment of Biocatalysis, Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080 Communicated by M. J. Osborn, December 19, 1985 ABSTRACT The sequence of the cloned Bacillus MATERIALS AND METHODS amyloliquefaciens subtilisin gene suggested that this secreted serine protease is produced as a larger precursor, designated T4 lysozyme was provided by Ron Wetzel (Genentech). T4 preprosubtilisin [Wells, J. A., Ferrari, E., Henner, D. J., DNA kinase was from Bethesda Research Laboratories. Estell, D. A. & Chen, E. Y. (1983) Nucleic Acids Res. 11, BamHI, EcoRI, and T4 ligase were from New England 7911-7925]. Biochemical evidence presented here shows that a Biolabs. DNA polymerase large fragment (Klenow fragment) subtilisin precursor is produced in Bacillus subtilis hosts. The was obtained from Boehringer Mannheim. Enzymes were precursor is first localized in the cell membrane, reaching a used as recommended by their respective suppliers. Eugenio steady-state level of -1000 sites per cell. Mutations in the Ferrari and Dennis Henner kindly provided the following B. subtilisin gene that alter a catalytically critical residue (i.e., subtilis strains used in these studies (6, 14): BG2036 (Apr-, aspartate +32 -* asparagine), or delete the carboxyl-terminal Npr-), BG2019 (Apr-, Npr+), BG2044 (Apr', Npr-), and portion of the enzyme that contains catalytically critical resi- I-168 (Apr', Npr+).
    [Show full text]
  • IL-33 Is Processed Into Mature Bioactive Forms by Neutrophil Elastase and Cathepsin G
    IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G Emma Lefrançais, Stephane Roga, Violette Gautier, Anne Gonzalez-de-Peredo, Bernard Monsarrat, Jean-Philippe Girard1,2, and Corinne Cayrol1,2 Centre National de la Recherche Scientifique, Institut de Pharmacologie et de Biologie Structurale, F-31077 Toulouse, France; Université de Toulouse, Université Paul Sabatier, Institut de Pharmacologie et de Biologie Structurale, F-31077 Toulouse, France Edited* by Charles A. Dinarello, University of Colorado Denver, Aurora, CO, and approved December 19, 2011 (received for review October 3, 2011) Interleukin-33 (IL-33) (NF-HEV) is a chromatin-associated nuclear activity (4). However, we (23) and others (24–26) demonstrated cytokine from the IL-1 family, which has been linked to important that full-length IL-33 is biologically active and that processing of diseases, including asthma, rheumatoid arthritis, ulcerative colitis, IL-33 by caspases results in its inactivation, rather than its activa- and cardiovascular diseases. IL-33 signals through the ST2 receptor tion. Further analyses revealed that IL-33 is constitutively and drives cytokine production in type 2 innate lymphoid cells (ILCs) expressed to high levels in the nuclei of endothelial and epithelial (natural helper cells, nuocytes), T-helper (Th)2 lymphocytes, mast cells in vivo (27) and that it can be released in the extracellular cells, basophils, eosinophils, invariant natural killer T (iNKT), and space after cellular damage (23, 24). IL-33 was, thus, proposed (23, natural killer (NK) cells. We and others recently reported that, unlike 24, 27) to function as an endogenous danger signal or alarmin, IL-1β and IL-18, full-length IL-33 is biologically active independently similar to IL-1α and high-mobility group box 1 protein (HMGB1) of caspase-1 cleavage and that processing by caspases results in IL-33 (28–32), to alert cells of the innate immune system of tissue inactivation.
    [Show full text]